Search Within

Matthew J Matasar

Formats
  1. Meeting Abstract (190)
  2. Journal Article (85)
  3. Book Section (4)
  4. Review (3)
  5. Correspondence (2)
  6. Editorial (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (290)
  2. Department of Medicine (290)
  3. Hematologic Malignancies, Division of (290)
  4. Lymphoma (290)
  5. Survivorship Research (290)
  6. Population Sciences Research Program (111)

More Groups

People
  1. Andrew Zelenetz (116)
  2. David Straus (102)
  3. Ariela Noy (98)
  4. Paul Hamlin (98)
  5. Steven Horwitz (96)
  6. Alison Moskowitz (95)

More People

Years
  1. 2024 (6)
  2. 2023 (12)
  3. 2022 (43)
  4. 2021 (43)
  5. 2020 (23)
  6. 2019 (34)

More Years

Publications
  1. Blood (108)
  2. Journal of Clinical Oncology (37)
  3. Hematological Oncology (22)
  4. Biology of Blood and Marrow Transplantation (11)
  5. Clinical Lymphoma, Myeloma and Leukemia (11)
  6. Blood Advances (10)

More Publications

Publishers
  1. American Society of Hematology (118)
  2. American Society of Clinical Oncology (37)
  3. Elsevier Inc. (28)
  4. Wiley Blackwell (26)
  5. Oxford University Press (13)
  6. John Wiley & Sons (10)

More Publishers

Results (290)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pooled safety analysis from phase I-III studies for patients with hematological malignancies treated with the PI3K inhibitor copanlisib
    Meeting Abstract

    Zinzani, P. L.; Özcan, M.; Capra, M.; Santoro, A.; Panayiotidis, P.; Bouabdallah, K.; Jurczak, W.; Phelps, C.; Hiemeyer, F. J. R.; Soler, L. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • LymphGen classification of diffuse large B-cell lymphoma in a cohort of adolescent and young adult (AYA) patients
    Meeting Abstract

    Cabal, A.; Zhu, M.; Uppal, M.; Joffe, E.; Batlevi, C. L.; Matasar, M. J.; Okwali, M.; Dogan, A.; Zelenetz, A. D.; Salles, G.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma
    Meeting Abstract

    Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
    Blood (2022)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2
    Meeting Abstract

    Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M. J.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study
    Meeting Abstract

    Herrera, A. F.; McCord, R.; Kimes, P.; Jardin, F.; Lenz, G.; Trneny, M.; Flowers, C. R.; Sehn, L. H.; Salles, G.; Sharman, J. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Herrera, A. F.; Chen, L.; Crombie, J. L.; Cohen, J. B.; Advani, R. H.; LaCasce, A. S.; Popplewell, L. L.; Puverel, S.; Peters, L.; Daniels, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
    Meeting Abstract

    Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL
    Meeting Abstract

    Matasar, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
    Annals of Oncology (2022)

    Fulltext@MSK | Save